Exclusive Summary

• Potential First-in-Class oral Kv1.3 inhibitor that selectively targets Effector Memory T (TEM) cells, offering a safer immunomodulatory approach compared to broad immunosuppressants.
• Superior pre-clinical efficacy demonstrated in IBD models against standard-of-care Mesalamine and the JAK inhibitor Tofacitinib.
• Proprietary ASD (Amorphous Solid Dispersion) formulation technology significantly enhances bioavailability (>20-fold) and ensures high tissue concentration in the intestine.
• Validated high-value asset class: comparable pipeline assets (e.g., DES-7114) have secured $500M+ deals, making UB029 an attractive licensing opportunity for partners seeking safe oral IBD therapies.

Asset Materials

Contact Us for Full Materials